Dicot's potency drug candidate demonstrates efficiency and long duration even at a low dose
Press release: Uppsala, December 2, 2021. Dicot's latest animal study demonstrates effect of the drug candidate LIB-01 even at low dose and the 7-day duration of effect on erectile function was confirmed, which provides solid ground for coming clinical studies in humans.As previously reported, Dicot is conducting animal studies in collaboration with the French contract laboratory Pelvipharm, where the drug candidate LIB-01's effect on erectile function is tested in both healthy rats and in animals in a disease model. The latest results from studies conducted on healthy rats confirm